Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myeloid, Acute 25Leukemia 13Neuroblastoma 12Myelodysplastic Syndromes 12Multiple Myeloma 12Recurrence 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Lymphoma 8Sarcoma 7Medulloblastoma 7Astrocytoma 7Lymphoma, Non-Hodgkin 6Wilms Tumor 5Osteosarcoma 5Central Nervous System Neoplasms 5Brain Neoplasms 5Sarcoma, Ewing 4Rhabdoid Tumor 4Retinoblastoma 4Optic Nerve Glioma 4Neoplasms 4Myeloproliferative Disorders 4Lymphoma, Mantle-Cell 4Lymphoma, Follicular 4Leukemia, Lymphocytic, Chronic, B-Cell 4Leukemia, Biphenotypic, Acute 4Hodgkin Disease 4Hematologic Neoplasms 4Burkitt Lymphoma 4Testicular Neoplasms 3

Interventions

oblimersen 1Razoxane 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Exercise 1Doxorubicin 1Dexrazoxane 1Cyclophosphamide 1Carvedilol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Cardiotoxicity × Granulocyte Colony-Stimulating Factor × Clear all
NCT00039481 2013-01-17

Oblimersen Plus Combination Chemotherapy and Dexrazoxane in Treating Children and Adolescents With Relapsed or Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 1 Completed
15 enrolled

Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡